E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Review Article

Online Publishing Date:
22 / 01 / 2022

 


Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials

Sharanabasayyaswamy Basayya Hiremath, Srinivas Lokikere Devendrappa.


Abstract
Background: Acute migraine is the most common disabling chronic neurological disorder in the world. There are a huge proportion of unmet needs in treatment efficacy and satisfaction with currently available drugs and hence need for newer agents. One such FDA-approved drug is 5-HT1F Agonist lasmiditan.

Aim and Objective: The present review and meta-analysis were conducted with the objectives to analyze and review safety and efficacy of lasmiditan.

Materials and Methods: Electronic database search in PUBMED and Cochrane Library was conducted using search terms ?Lasmiditan? OR ?5-HT1F Agonist.? Randomized or cross-over studies comparing safety and/or efficacy of oral lasmiditan versus other active treatment or placebo in adults with acute attack of migraine were included in the analysis. Incidences of ?2 h pain-free? events were the primary outcome measure while the incidences of adverse drug events and control of other migraine-associated symptoms were the secondary outcome measures compared. Inverse variance method and both random and fixed effect models were used in the analysis by RevMan 5.3 software.

Results: At 2 h, freedom from pain (odds ratio: 2.02, 95% CI: 1.76, 2.31, n = 4395), most bothersome symptom, photophobia, and phonophobia were observed at significantly highest rates in 200 mg lasmiditan group than in placebo group. In decreasing order, incidences of dizziness, fatigue, ≥1 serious adverse drug reaction, paresthesia, and somnolence were significantly higher with 200 mg lasmiditan than placebo.

Conclusion: Higher the dose of lasmiditan used, rapid and stronger is its pain aborting action. Lasmiditan has effective and sustained effect up to 48 h, and hence, there is a need to analyze its potential migraine preventive effects.

Key words: Lasmiditan; Migraine; 5-HT1F Agonist


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Sharanabasayyaswamy Basayya Hiremath
Articles by Srinivas Lokikere Devendrappa
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Hiremath SB, Devendrappa SL. Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials. Natl J Physiol Pharm Pharmacol. 2022; 12(9): 1317-1324. doi:10.5455/njppp.2022.12.01019202212012022

Web Style

Hiremath SB, Devendrappa SL. Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials. https://www.njppp.com/?mno=141058 [Access: March 14, 2024]. doi:10.5455/njppp.2022.12.01019202212012022

AMA (American Medical Association) Style

Hiremath SB, Devendrappa SL. Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials. Natl J Physiol Pharm Pharmacol. 2022; 12(9): 1317-1324. doi:10.5455/njppp.2022.12.01019202212012022


Vancouver/ICMJE Style

Hiremath SB, Devendrappa SL. Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials. Natl J Physiol Pharm Pharmacol. (2022), [cited March 14, 2024]; 12(9): 1317-1324. doi:10.5455/njppp.2022.12.01019202212012022


Harvard Style

Hiremath, S. B. & Devendrappa, . S. L. (2022) Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials. Natl J Physiol Pharm Pharmacol, 12 (9), 1317-1324. doi:10.5455/njppp.2022.12.01019202212012022


Turabian Style

Hiremath, Sharanabasayyaswamy Basayya, and Srinivas Lokikere Devendrappa. 2022. Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials. National Journal of Physiology, Pharmacy and Pharmacology, 12 (9), 1317-1324. doi:10.5455/njppp.2022.12.01019202212012022


Chicago Style

Hiremath, Sharanabasayyaswamy Basayya, and Srinivas Lokikere Devendrappa. "Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 1317-1324. doi:10.5455/njppp.2022.12.01019202212012022


MLA (The Modern Language Association) Style

Hiremath, Sharanabasayyaswamy Basayya, and Srinivas Lokikere Devendrappa. "Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials." National Journal of Physiology, Pharmacy and Pharmacology 12.9 (2022), 1317-1324. Print. doi:10.5455/njppp.2022.12.01019202212012022


APA (American Psychological Association) Style

Hiremath, S. B. & Devendrappa, . S. L. (2022) Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials. National Journal of Physiology, Pharmacy and Pharmacology, 12 (9), 1317-1324. doi:10.5455/njppp.2022.12.01019202212012022


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272